Monopar Therapeutics Inc

MNPR10 Dec 2024
Healthcare
$22.1
+0.04 (+3.63%)
Lowest Today
$21
Highest Today
$22.92
Today’s Open
$22.1
Prev. Close
$21.5
52 Week High
$38.5
52 Week Low
$1.4
To Invest in Monopar Therapeutics Inc

Monopar Therapeutics Inc

Healthcare
MNPR10 Dec 2024
+0.04 (+3.63%)
1M
3M
6M
1Y
5Y
Low
$21
Day’s Range
High
$22.92
21
52 Week Low
$1.4
52-Week Range
52 Week High
$38.5
1.4
1 Day
-
1 Week
-4.48%
1 month return
+32.89%
3 month return
+481.77%
6 month return
+2808.09%
1 Year return
+6827.13%
3 Years return
+459.89%
5 Years return
-10.64%
10 Years return
-
Institutional Holdings
Geode Capital Management, LLC
0.27
Vanguard Institutional Extnd Mkt Idx Tr
0.17
Fidelity Extended Market Index
0.17
Fidelity Total Market Index
0.1
Fidelity Nasdaq Composite Index
0.05
Fidelity Series Total Market Index
0.05
Spartan Extended Market Index Pool E
0.03

Market Status

Fundamentals
Market Cap
113.47 mln
PB Ratio
22.94
PE Ratio
0
Enterprise Value
106.21 mln
Total Assets
7.35 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
Organisation
Monopar Therapeutics Inc
Employees
9
Industry
Biotechnology
CEO
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities